Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis
Sponsor: UCB Biopharma SRL
Summary
The primary purpose of this study is to compare the efficacy of bimekizumab administered subcutaneously (sc) for 16 weeks versus placebo in the treatment of study participants with moderate to severe plaque psoriasis (PSO).
Official title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
133
Start Date
2023-10-31
Completion Date
2025-02-05
Last Updated
2026-06-26
Healthy Volunteers
No
Interventions
Placebo
Study participants will receive placebo subcutaneously at pre-specified time points in the placebo arm as comparator and in the bimekizumab arm to maintain the blinding.
Bimekizumab
Study participants will receive bimekizumab (dosage regimen 1 and 2) subcutaneously administered at pre-specified time points during the Initial and Maintenance Treatment Periods.
Locations (18)
Ps0041 20023
Beijing, China
Ps0041 20247
Beijing, China
Ps0041 20306
Beijing, China
Ps0041 20117
Guangzhou, China
Ps0041 20311
Guangzhou, China
Ps0041 20313
Guangzhou, China
Ps0041 20022
Hangzhou, China
Ps0041 20193
Hangzhou, China
Ps0041 20296
Hangzhou, China
Ps0041 20312
Jinan, China
Ps0041 20318
Jinan, China
Ps0041 20310
Ningbo, China
Ps0041 20308
Shanghai, China
Ps0041 20184
Shenzhen, China
Ps0041 20136
Tianjin, China
Ps0041 20120
Wuhan, China
Ps0041 20314
Wuxi, China
Ps0041 20309
Xi'an, China